Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-05-09
1996-07-09
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514259, 514311, 514307, 514302, 514451, 514453, 514460, A61K 3147, A61K 31505, A61K 3144, A61K 3135
Patent
active
055345247
ABSTRACT:
The present invention focuses upon a method for inhibiting bone resorption. This method involves administering a 5-lipoxygenase inhibitor to a subject in an amount inhibiting the effects of an osteoclast-stimulating factor. When the production of the osteoclast-stimulating factors such as PTH, PTHrp, IL-1, TNF, LT, 1,25(OH).sub.2 D.sub.3 or other factors which may stimulate the production of 5-LO metabolites via the 5-lipoxygenase pathway is inhibited, bone resorption markedly declines. The direct osteoclast-stimulating factors include leukotriene, peptidoleukotriene and 5-hydroxyeicosatetraenoic acid. Other factors yet to be identified or previously known may also be 5-lipoxygenase metabolites that stimulate bone resorption. While 5-lipoxygenase inhibitors may be substrate analogs or allosteric inhibitors, a substance which inhibits the activity of this enzyme may utilize other mechanisms (e.g., inhibition of 5-LO biosynthesis) and nevertheless function to inhibit bone resorption. Preferred inhibitors included NGDA, MK886 and ZM230,487. The best inhibitor thus far noted is ZM230,487. The inhibition of bone resorption is highly desirable with, for example, periodontal disease, osteoporosis, estrogen deficiency, Paget's disease, inflammatory bone loss, bone malignancy, hyperparathyroidism. The preferred range of 5-lipoxygenase inhibitors administered is from 0.1 to 10 mg/kg body weight/day.
REFERENCES:
Agarwal et al., "Nordihydroguaiaretic Acid, an Inhibition of Lipoxygenase, also Inhibits Cytochrome P-450-Medicate Monooxygenase Activity in Rat Epidermal and Hepatic Microsome," Drug Metabolism and Disposition, 19(3): 620-623, 1991.
Crawley et al., "Methoxytetrahydropyrans. A New Series of Selective and Orally Potent 5-Lipoxygenase Inhibitors," J. Med. Chem., 35:2600-2609, 1992.
Gallwitz et al., "5-Lipoxygenase Metabolites of Arachidonic Acid Stimulate Isolated Osteoclasts to Resorb Calcified Matrices," The Journal of Biological Chemistry, 268(14):10087-10094, 1993.
Huang et al., "Differential Effects of a Series of Hydroxamic Acid Derivatives on 5-Lipoxygenase and Cyclooxygenase from Neutrophils and 12-Lipoxygenase from Platelets and Their In Vivo Effects on Inflammation and Anaphylaxis," J. Med. Chem., 32:1836-1842, 1989.
Gillard et al., "L-663, 536 (MK-886) (3-[1-(4-chlorobenzyl)-3-butylthio-5-isoproylindol-2-yl]-2,2-dimethylpropa noic acid), a novel, orally active leukotriene biosynthesis inhibitor," Can. J. Physiol. Pharmacol., 67:456-464, 1989.
McMillan et al., "Pre-clinical Pharmacology of ICI D2138, a Potent Orally-Active Non-Redox Inhibitor of 5-Lipoxygenase," Br. J. Pharmacol., 107:1042-1047, 1992.
Oreffo et al., "Inhibitory Effects of the Bone-Derived Growth Factors Osteoinductive Factor and Transforming Growth Factor-.beta. on Isolated Osteoclasts," Endocrinlogy, 126(6):3069-3075, 1990.
Oreffo et al., "Characterization of a Cell Line Derived From a Human Giant Cell Tumor that Stimulates Osteoclastic Bone Resorption," Clinical Orthopaedics and Related Research, 296:229-241, 1993.
Mundy, "Cytokines and growth factors in the regulation of bone remodeling," J. Bone Miner. Res., 8/Suppl.2:S505-S510, 1993.
Sietsema et al., "Absorption, Bioavailability, and Pharmacokinetics of Tebufelone in the Rat," Journal of Pharmaceutical Sciences, 82, 6:610-612, 1993.
Wiesenberg-Boettcher et al., "The Pharmacological Profile of CGP 28238, A Novel Highly Potent Anti-Inflammatory Compound," Drugs Exptl. Clin. Res., 15 11/12:501-509, 1989.
Bonewald Lynda
Gallwitz Wolf E.
Mundy G. R.
Board of Regents , The University of Texas System
Criares Theodore J.
LandOfFree
Suppression of bone resorption by quinolines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Suppression of bone resorption by quinolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Suppression of bone resorption by quinolines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1867442